Trial Outcomes & Findings for Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer (NCT NCT02157519)

NCT ID: NCT02157519

Last Updated: 2018-11-19

Results Overview

The Morisky Medication Adherence Questionnaire (MMAS-4) - a 4-item questionnaire that assesses medication adherence in the past week by asking patients to indicate "yes" or "no" to each item (self-report). The four items ask patients to self-report whether they forgot to take their oral chemotherapy (OC) medication in the past week, whether they had any problems remembering to take their OC medication in the last week, whether they stopped taking their OC medication when they felt better in the past week, and whether they stopped taking their OC medication when they felt worse in the past week. Participants who answered "yes" to any of the four items were coded as having adherence problems, while those who indicated "no" to all four items were coded as having no adherence problems. Therefore, the count of participants is the number of participants who reported any difficulties with adherence on any of the four items in the past week.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

212 participants

Primary outcome timeframe

Post-Assessment (12-14 weeks after baseline) controlling for baseline assessment

Results posted on

2018-11-19

Participant Flow

From 2/13/15-12/31/16, patients with diverse malignancies were recruited from the outpatient oncology clinics at Massachusetts General Hospital Cancer Center and three community affiliates (i.e., Mass General/North Shore Cancer Center, Mass General Cancer Center at Mass General West, Mass General Cancer Center at Emerson Hospital-Bethke).

Of the 212 patients enrolled in our study, 181 were randomized. There were 28 participants who dropped out of the study after enrollment but prior to randomization, and 3 participants who were lost to follow-up after enrollment but prior to randomization.

Participant milestones

Participant milestones
Measure
Mobile Application Intervention
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Overall Study
STARTED
91
90
Overall Study
MEMScap Collected
84
86
Overall Study
COMPLETED
80
89
Overall Study
NOT COMPLETED
11
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Mobile Application Intervention
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Overall Study
Death
3
1
Overall Study
Withdrawal by Subject
7
0
Overall Study
Lost to Follow-up
1
0

Baseline Characteristics

Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Mobile Application Intervention
n=91 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=90 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Total
n=181 Participants
Total of all reporting groups
Age, Continuous
52.9 years
STANDARD_DEVIATION 13.7 • n=99 Participants
53.8 years
STANDARD_DEVIATION 12.1 • n=107 Participants
53.3 years
STANDARD_DEVIATION 12.9 • n=206 Participants
Sex: Female, Male
Female
46 Participants
n=99 Participants
51 Participants
n=107 Participants
97 Participants
n=206 Participants
Sex: Female, Male
Male
45 Participants
n=99 Participants
39 Participants
n=107 Participants
84 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
3 Participants
n=107 Participants
3 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
87 Participants
n=99 Participants
82 Participants
n=107 Participants
169 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants
n=99 Participants
5 Participants
n=107 Participants
9 Participants
n=206 Participants
Race/Ethnicity, Customized
White
84 Participants
n=99 Participants
75 Participants
n=107 Participants
159 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian
6 Participants
n=99 Participants
4 Participants
n=107 Participants
10 Participants
n=206 Participants
Race/Ethnicity, Customized
African American or Black
0 Participants
n=99 Participants
5 Participants
n=107 Participants
5 Participants
n=206 Participants
Race/Ethnicity, Customized
Hispanic/Latino/a
0 Participants
n=99 Participants
4 Participants
n=107 Participants
4 Participants
n=206 Participants
Race/Ethnicity, Customized
Multiracial
0 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG = 0
40 Participants
n=99 Participants
49 Participants
n=107 Participants
89 Participants
n=206 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG = 1
47 Participants
n=99 Participants
40 Participants
n=107 Participants
87 Participants
n=206 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG = 2
4 Participants
n=99 Participants
1 Participants
n=107 Participants
5 Participants
n=206 Participants
Cancer Type
Hematologic
30 Participants
n=99 Participants
30 Participants
n=107 Participants
60 Participants
n=206 Participants
Cancer Type
Non-small cell lung cancer
17 Participants
n=99 Participants
16 Participants
n=107 Participants
33 Participants
n=206 Participants
Cancer Type
Breast
11 Participants
n=99 Participants
15 Participants
n=107 Participants
26 Participants
n=206 Participants
Cancer Type
High grade Glioma
9 Participants
n=99 Participants
12 Participants
n=107 Participants
21 Participants
n=206 Participants
Cancer Type
Sarcoma
8 Participants
n=99 Participants
4 Participants
n=107 Participants
12 Participants
n=206 Participants
Cancer Type
Gastrointestinal
6 Participants
n=99 Participants
2 Participants
n=107 Participants
8 Participants
n=206 Participants
Cancer Type
Melanoma
4 Participants
n=99 Participants
3 Participants
n=107 Participants
7 Participants
n=206 Participants
Cancer Type
Genito-urinary
4 Participants
n=99 Participants
3 Participants
n=107 Participants
7 Participants
n=206 Participants
Cancer Type
Low grade Glioma
1 Participants
n=99 Participants
4 Participants
n=107 Participants
5 Participants
n=206 Participants
Cancer Type
Non-GIST Sarcoma
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Oral Therapy Type
Targeted therapy
65 Participants
n=99 Participants
56 Participants
n=107 Participants
121 Participants
n=206 Participants
Oral Therapy Type
Chemotherapy
26 Participants
n=99 Participants
34 Participants
n=107 Participants
60 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Post-Assessment (12-14 weeks after baseline) controlling for baseline assessment

Population: Analysis population is the number of participants who completed the post-assessment measure of the MMAS-4

The Morisky Medication Adherence Questionnaire (MMAS-4) - a 4-item questionnaire that assesses medication adherence in the past week by asking patients to indicate "yes" or "no" to each item (self-report). The four items ask patients to self-report whether they forgot to take their oral chemotherapy (OC) medication in the past week, whether they had any problems remembering to take their OC medication in the last week, whether they stopped taking their OC medication when they felt better in the past week, and whether they stopped taking their OC medication when they felt worse in the past week. Participants who answered "yes" to any of the four items were coded as having adherence problems, while those who indicated "no" to all four items were coded as having no adherence problems. Therefore, the count of participants is the number of participants who reported any difficulties with adherence on any of the four items in the past week.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=80 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=86 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Self-reported Difficulties With Adherence on Any of the Four MMAS-4 Items in the Past Week
11 Participants
20 Participants

PRIMARY outcome

Timeframe: Daily over course of study from baseline (within 2 weeks after enrollment) to post assessment (12-14 weeks after baseline)

Population: Analysis population is the number of participants who had data available from the Medication Event Monitoring System (MEMS) and completed the Multidimensional Scale of Perceived Social Support (MSPSS) at both the baseline and post assessments.

Medication Event Monitoring System (MEMS) utilizes an electronic pill cap to record the date and time the pill dispenser was opened.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=75 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=83 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Adherence to Oral Chemotherapy Medication
81.50 percentage of medication taken
Standard Deviation 2.93
79.16 percentage of medication taken
Standard Deviation 2.78

PRIMARY outcome

Timeframe: Change score between 1) Baseline (within 2 weeks after enrollment) and 2) Post-Assessment (12-14 weeks after baseline)

Population: Participants who completed both baseline and post measures of the MDASI and the Multidimensional Scale of Perceived Social Support (MSPSS). Due to a clerical error, the MDASI was not administered to 31 pts at baseline. One pt skipped the symptom interference scale, causing a discrepancy in the number of pts completing each subscale on the MDASI.

M.D. Anderson Symptom Inventory (MDASI): a 19-item instrument that assesses the most common symptoms and side effects related to cancer and its treatment (self-report). The MDASI uses a 0-10 numerical rating scale for all items to assess the severity and interference of symptoms patients have experienced in the past 24 hours, with 0 being "not present" or "did not interfere" and 10 being "as bad as you can imagine" or "interfered completely". The ratings in the MDASI are averaged into two subscale scores: mean symptom severity (13 symptom items) and mean interference (6 interference items only), with possible scores on both subscales ranging from 0-10. Higher scores indicate worse symptom severity and interference, while lower scores indicate less symptom severity and interference.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=67 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=71 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Change in Symptoms and Side Effects
Change in Symptom Severity
-0.03 units on MDASI scale
Standard Error 0.15
0.08 units on MDASI scale
Standard Error 0.15
Change in Symptoms and Side Effects
Change in Symptom Interference
-0.12 units on MDASI scale
Standard Error 0.23
-0.11 units on MDASI scale
Standard Error 0.23

PRIMARY outcome

Timeframe: Change score between 1) Baseline (within 2 weeks after enrollment) and 2) Post-Assessment (12-14 weeks after baseline)

Population: Analysis population is the number of participants who completed both baseline and post-assessment measures of the FACT-General (FACT-G) and the Multidimensional Scale of Perceived Social Support (MSPSS)

Functional Assessment of Cancer Treatment - General (FACT-G): a 27-item questionnaire that assesses physical, social, emotional, and functional well-being (self-report). The FACT-G utilizes a five-point scale from 0 (not at all) to 4 (very much). Four subscales are computed by taking the sum: physical well-being (7 items; range 0-28), social/family well-being (7 items; range 0-28), emotional well-being (7 items; range 0-24), and functional well-being (7 items; range 0-28). The overall score is the sum of the four subscale scores (range 0-108). Higher scores indicate greater quality of life, while lower scores indicate a worse quality of life.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=78 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=86 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Change in Quality of Life
FACT-General
0.49 units on the FACT-G scale
Standard Error 1.19
-1.93 units on the FACT-G scale
Standard Error 1.13
Change in Quality of Life
FACT-Physical Well-Being
0.81 units on the FACT-G scale
Standard Error 0.48
0.11 units on the FACT-G scale
Standard Error 0.45
Change in Quality of Life
FACT-Social Well-Being
-0.55 units on the FACT-G scale
Standard Error 0.53
-2.22 units on the FACT-G scale
Standard Error 0.50
Change in Quality of Life
FACT-Emotional Well-Being
0.04 units on the FACT-G scale
Standard Error 0.41
0.53 units on the FACT-G scale
Standard Error 0.40
Change in Quality of Life
FACT-Functional Well-Being
0.35 units on the FACT-G scale
Standard Error 0.43
-0.40 units on the FACT-G scale
Standard Error 0.41

SECONDARY outcome

Timeframe: Change score between 1) Baseline (within 2 weeks after enrollment) and 2) Post-Assessment (12-14 weeks after baseline)

Population: Analysis population is the number of participants who completed both baseline and post-assessment measures of the FACIT-TS-PS and the Multidimensional Scale of Perceived Social Support (MSPSS)

Description: Functional Assessment of Chronic Illness Treatment-Treatment Satisfaction-Patient Satisfaction (FACIT-TS-PS), 21-items that assesses patient satisfaction with doctor and staff competence, communication, and confidence and trust in providers, as well as overall satisfaction of care (self-report). The FACIT-TS-PS uses a 0-3 numerical rating scale to assess satisfaction with healthcare, with 0 representing the lowest level of satisfaction and 3 representing the highest level of satisfaction. Four subscales are computed by taking the sum: explanations (4 items; range 0-12), interpersonal (3 items, range 0-9), comprehensive care (7 items; range 0-21), nurses (3 items; range 0-9), and trust (4 items; range 0-12). A higher score indicates greater satisfaction with care, while a lower score represents lower satisfaction with care.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=78 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=86 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Treatment Satisfaction
FACIT-Clinician Explanations
0.04 units on FACIT-TS-PS scale
Standard Deviation 0.20
-0.34 units on FACIT-TS-PS scale
Standard Deviation 0.19
Treatment Satisfaction
FACIT-Interpersonal Treatment
0.07 units on FACIT-TS-PS scale
Standard Deviation 0.13
-0.29 units on FACIT-TS-PS scale
Standard Deviation 0.13
Treatment Satisfaction
FACIT-Comprehensive Care
0.08 units on FACIT-TS-PS scale
Standard Deviation 0.52
-0.89 units on FACIT-TS-PS scale
Standard Deviation 0.49
Treatment Satisfaction
FACIT-Nursing Care
-0.45 units on FACIT-TS-PS scale
Standard Deviation 0.20
-0.26 units on FACIT-TS-PS scale
Standard Deviation 0.19
Treatment Satisfaction
FACIT-Trust in Clinicians
-0.24 units on FACIT-TS-PS scale
Standard Deviation 0.13
-0.24 units on FACIT-TS-PS scale
Standard Deviation 0.12

SECONDARY outcome

Timeframe: Post-Assessment (12-14 weeks after baseline)

Population: Analysis population is the number of participants who completed both baseline and post-assessment measures of the Resource Utilization Questionnaire (RUQ) and the Multidimensional Scale of Perceived Social Support (MSPSS)

Resource Utilization Questionnaire, an adapted 3-item questionnaire inquiring about the number of emergency department visits and hospitalizations over the past three months (self-report). Patients are asked to indicate how many times they have gone to the emergency room in the past three months on a numerical scale ranging from 0 to "5 or more". Scores ranged from 0-5. A higher score represents more frequent emergency department visits, indicating higher resource utilization.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=78 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=84 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Emergency Department Visits
0.16 Scores on a scale
Standard Deviation 0.04
0.14 Scores on a scale
Standard Deviation 0.04

SECONDARY outcome

Timeframe: Post-Assessment (12-14 weeks after baseline)

Population: Analysis population is the number of participants who completed both baseline and post-assessment measures of the Resource Utilization Questionnaire (RUQ) and the Multidimensional Scale of Perceived Social Support (MSPSS).

Description: Resource Utilization Questionnaire, an adapted 3-item questionnaire inquiring about the number of emergency department visits and hospitalizations over the past three months (self-report). Patients are asked to indicate how many times they have been admitted to the hospital in the past three months on a numerical scale ranging from 0 to "5 or more". Scores ranged from 0-5. A higher score represents more frequent hospital admissions, indicating higher resource utilization.

Outcome measures

Outcome measures
Measure
Mobile Application Intervention
n=76 Participants
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=84 Participants
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Hospitalizations
0.20 Scores on a scale
Standard Deviation 0.07
0.15 Scores on a scale
Standard Deviation 0.07

Adverse Events

Mobile Application Intervention

Serious events: 0 serious events
Other events: 1 other events
Deaths: 3 deaths

Standard Oncology Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Mobile Application Intervention
n=91 participants at risk
Mobile Application Intervention: Participants assigned to the intervention group received the mobile application intervention for approximately three months after enrollment. The mobile app intervention consisted of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app were transmitted weekly to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Standard Oncology Care
n=90 participants at risk
Participants in the control group received standard oncology care only, and completed baseline and post-assessments.
Product Issues
Adherence data of one study participant was lost in the mail
1.1%
1/91 • Number of events 1 • Adverse event data were collected during the active study period (study enrollment through post-assessment completion). As this was a behavioral intervention, adverse events were not assessed at any pre-specified time. Rather, they were recorded as reported by participants at any point during their study participation.
As advanced cancer is a chronic-type illness, regular fluctuations in cancer-related symptoms, disease worsening, hospitalizations, emergency department visits, and deaths are to be expected, are not study-related, and will not be considered or reported as adverse events for the purposes of this study. Adverse events or unanticipated events that were study-related (e.g., security or privacy breaches) were reported to the IRB at the discretion of the PI.
0.00%
0/90 • Adverse event data were collected during the active study period (study enrollment through post-assessment completion). As this was a behavioral intervention, adverse events were not assessed at any pre-specified time. Rather, they were recorded as reported by participants at any point during their study participation.
As advanced cancer is a chronic-type illness, regular fluctuations in cancer-related symptoms, disease worsening, hospitalizations, emergency department visits, and deaths are to be expected, are not study-related, and will not be considered or reported as adverse events for the purposes of this study. Adverse events or unanticipated events that were study-related (e.g., security or privacy breaches) were reported to the IRB at the discretion of the PI.

Additional Information

Joseph Greer, PhD

Massachusetts General Hospital Cancer Center

Phone: 617-643-2143

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place